Welcome to Britecyte
Our Vision
"We are pioneering regenerative medicine therapies through biocompatible cells and tissue."
Britecyte is a biotechnology company focused on the development of regenerative medicine therapies. Our pipeline includes biologic therapies and tissue allografts for a broad variety of indications. Our lead program is a biologic therapy for non-alcoholic steatohepatitis (NASH).
The Science
Metabolic disease impairs millions of lives resulting in low quality of life with high morbidity and mortality. Non-alcoholic steatohepatitis (NASH) is a serious liver disease triggered by disrupted metabolism.
Britecyte is developing a biologic therapy that targets multiple pathways in NASH and in adipose tissue metabolism, the root cause of NASH. In addition to biologic therapies, Britecyte is focusing on innovative regenerative medicine products for the repair of soft tissue defects, with a fast path to market.
